1. Home
  2. IMRN vs ANY Comparison

IMRN vs ANY Comparison

Compare IMRN & ANY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMRN
  • ANY
  • Stock Information
  • Founded
  • IMRN 1994
  • ANY N/A
  • Country
  • IMRN Australia
  • ANY United States
  • Employees
  • IMRN N/A
  • ANY N/A
  • Industry
  • IMRN Biotechnology: Pharmaceutical Preparations
  • ANY Finance: Consumer Services
  • Sector
  • IMRN Health Care
  • ANY Finance
  • Exchange
  • IMRN Nasdaq
  • ANY Nasdaq
  • Market Cap
  • IMRN 15.0M
  • ANY 25.5M
  • IPO Year
  • IMRN N/A
  • ANY N/A
  • Fundamental
  • Price
  • IMRN $1.95
  • ANY $0.93
  • Analyst Decision
  • IMRN Strong Buy
  • ANY Strong Buy
  • Analyst Count
  • IMRN 1
  • ANY 1
  • Target Price
  • IMRN $5.00
  • ANY $3.00
  • AVG Volume (30 Days)
  • IMRN 5.4K
  • ANY 762.2K
  • Earning Date
  • IMRN 01-07-2025
  • ANY 11-14-2024
  • Dividend Yield
  • IMRN N/A
  • ANY N/A
  • EPS Growth
  • IMRN N/A
  • ANY N/A
  • EPS
  • IMRN N/A
  • ANY N/A
  • Revenue
  • IMRN $3,271,194.00
  • ANY $21,657,000.00
  • Revenue This Year
  • IMRN N/A
  • ANY N/A
  • Revenue Next Year
  • IMRN N/A
  • ANY $16.70
  • P/E Ratio
  • IMRN N/A
  • ANY N/A
  • Revenue Growth
  • IMRN 171.67
  • ANY 38.44
  • 52 Week Low
  • IMRN $1.59
  • ANY $0.67
  • 52 Week High
  • IMRN $5.96
  • ANY $3.91
  • Technical
  • Relative Strength Index (RSI)
  • IMRN 43.88
  • ANY 35.77
  • Support Level
  • IMRN $1.89
  • ANY $0.94
  • Resistance Level
  • IMRN $2.09
  • ANY $1.31
  • Average True Range (ATR)
  • IMRN 0.14
  • ANY 0.09
  • MACD
  • IMRN -0.02
  • ANY -0.04
  • Stochastic Oscillator
  • IMRN 9.09
  • ANY 3.40

About IMRN Immuron Limited

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

About ANY Sphere 3D Corp.

Sphere 3D Corp provides solutions for stand-alone storage and technologies that converge the traditional silos of compute, storage, and network into integrated hyper-converged or converged solution. Its Disk systems include HVE Converged and Hyper-converged Infrastructure. It generates the majority of its revenue from the services it offers. All of its revenue comes from the Americas. The Company has two operating segments: Digital Mining and Service and Product. The Digital Mining segment generates revenue from the digital currency, it earns through its bitcoin mining activities. The Service and Product segment generates revenue from long-term customer contracts for service contracts and extended service contract and the sale of products related to the Company's data storage product line.

Share on Social Networks: